Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl

RSC Chem Biol. 2022 Jul 6;3(8):1008-1012. doi: 10.1039/d2cb00108j. eCollection 2022 Aug 3.

Abstract

The d- and l-versions of the Bcr-Abl SH2 domain (12.7 kDa) were synthesized. Key optimizations included pseudoproline incorporation, N-terminal hydrophilic tail addition and mild N-acetoxy succinimide acetylation. Their folding and activity are as for the recombinant protein. Our results will enable engineering of mirror-image monobody antagonists of the central oncoprotein Bcr-Abl.